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Janus-faced amiodarone-induced
pneumopathy
given  and  therefore  they  were  interpreted  as  an  unusual











A  and  B).  The  bronchoalveolar  lavage  showed  a  significantTo  the  Editor,
Several  forms  of  pulmonary  disease  can  occur  among
patients  treated  with  amiodarone  (usually  delivered  as
an  antiarrhythmic  drug).  Computed  tomography  findings
indicative  of  amiodarone-induced  lung  disease  include  high-
attenuation  parenchymal-pleural  lesions  and  nonspecific
pulmonary  infiltrates.  Only  a  few  cases  in  the  literature
have  described  the  occurrence  of  amiodarone-induced  pul-
monary  disease  as  pulmonary  nodules.  The  authors  describe
a  patient  showing  bilateral,  peripheral,  predominantly  basalPlease  cite  this  article  in  press  as:  Cerri  S,  et  al.  Janus-fac
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ground-glass  and  reticular  opacities  consistent  with  a  non-
specific  interstitial  pneumonia  (NSIP)  radiological  pattern.
This  was  followed  by  the  occurrence  of  two  nodules  that
progressively  decreased  in  size  after  oral  steroids  had  been
Figure  1  Panels  A  and  B.  CT  scan  images  showing  predominantly  ba
reticular abnormalities  consistent  with  a  non-specific  interstitial  pne
appearance at  different  magnifications  of  transbronchial  biopsies  sh
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BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)APT).
A  79-year-old  man,  a  non-smoker  and  who  had  a  history
f  atrial  fibrillation,  was  treated  with  amiodarone  400  mg
aily  for  3  years.  During  the  last  2  months  of  treatment,  he
resented  with  exertional  dyspnea  and  dry  cough.  Respira-
ory  function  tests  revealed  a  restrictive  ventilatory  pattern
ith  a  moderate  reduction  in  carbon  dioxide  lung  diffusion
DLCO)  (14.3  mL/min/mmHg,  55%  of  predicted  value).  Chest
omputed  tomography  (CT)  showed  bilateral,  peripheral,
redominantly  basal  ground-glass  and  reticular  opacities
onsistent  with  a  NSIP  radiological  pattern  (Fig.  1,  panelsed  amiodarone-induced  pneumopathy.  Pulmonol.  2019.
sal,  bilateral,  peripheral  ground-glass  opacities  with  associated
umonia  (NSIP)  radiological  pattern.  Panels  C  and  D.  Histological
owing  areas  of  organized  fibrosis  with  fibrinous  exudates  and
lignant  cells.
mount  of  foamy  macrophages.  Transbronchial  lung  biopsy
f  the  right  lower  lobe  was  performed  and  the  histological
xamination  revealed  the  presence  of  septal  widening  with
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Figure  2  Panels  A  and  B.  CT  scan  images  showing  the  resolution  of  the  ground-glass  and  reticular  opacities  after  amiodarone























































anels C  and  D.  Follow-up  CT  images  showing  a  substantial  re
miodarone withdrawal.
ype  II  pneumocytes  hyperplasia,  areas  of  organized  inter-
titial  fibrosis  with  sporadic  fibrinous  exudates,  fibroblasts
nd  collagen  deposition  next  to  aggregates  of  inflammatory
ells  and  considerable  amount  of  foamy  histiocyets.  These
ndings  were  consistent  with  a  diagnosis  of  APT  (Fig.  1,  pan-
ls  C  and  D).  Other  etiologies  of  interstitial  lung  disease
ILD)  were  carefully  ruled  out.  Amiodarone  was  suspended
hile  prednisone  40  mg  daily  and  oral  anticoagulants  were
iven,  with  rapid  clinical  and  functional  recovery.  At  40
ays,  ground-glass  and  reticular  opacities  had  almost  com-
letely  resolved  on  CT  scan  while  two  soft-tissue  nodules
f  25  and  11  mm,  respectively,  were  identified  in  the  right
ostophrenic  sulcus  (Fig.  2,  panels  A  and  B).  Both  lesions  pre-
ented  elevated  density  on  CT  scan  images  with  Hounsfield
nit  (HU)  values  ranging  from  46  to  50.  The  patient  under-
ent  a  new  bronchoscopy  with  bronchoalveolar  lavage  of
he  right  lower  lobe,  but  microbiological  and  cytological
nvestigations  were  unremarkable.  A  tuberculin  skin  test  and
lood  serological  markers  for  autoimmunity,  inflammatory
nd  infectious  disease  were  also  performed  with  negative
esults.  Moreover  a  supplemental  investigation  was  con-
ucted  excluding  the  onset  of  new  drug  treatment,  trauma
r  exposure  to  environmental  agents.  Given  their  rapid
nset,  the  elevated  HU  values  and  the  exclusion  of  other
oherent  etiologies,  the  nodules  were  interpreted  as  anPlease  cite  this  article  in  press  as:  Cerri  S,  et  al.  Janus-fa
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nusual  subacute  manifestation  of  APT.  As  physical  insult
o  pulmonary  parenchyma  is  known  to  increase  susceptibil-




ion  in  size  of  the  right  costophrenic  nodules  18  months  after
sed,1 surgical  lung  biopsy  was  not  performed  and  radio-
ogical  follow-up  was  started.  At  18  months,  follow-up  CT
howed  a  considerable  reduction  in  the  size  of  both  lung
odules  (Fig.  2, panels  C  and  D)  and  the  clinical  condition  of
he  patient  was  unremarkable.
Amiodarone,  one  of  the  most  widely  used  antiarrhythmic
gents,  is  known  to  cause  adverse  lung  effects  in  approxi-
ately  5%  of  treated  patients.2 Several  risk  factors  for  the
evelopment  of  lung  complications  have  been  identified:
he  pre-existence  of  lung  disease  and/or  respiratory  fail-
re  requiring  high  oxygen  mixtures,  lower  respiratory  tract
nfections,  older  age,  treatment  duration  and  a  history  of
ardiothoracic  surgery.3 Since  the  patient  had  been  taking
miodarone  for  2  years  before  developing  respiratory  symp-
oms,  a  dose  accumulation  effect  might  be  suspected  in
his  case.2,3 For  most  patients,  the  diagnosis  of  amiodarone-
nduced  pneumopathy  relies  on  imaging.4 According  to
vailable  literature,  lung  involvement  presents  a  wide  range
f  possible  manifestations:  from  asymptomatic  lipoid  pneu-
onia,  which  is  usually  named  the  ‘amiodarone  effect’,
o  the  ‘amiodarone  toxicity’  spectrum,  which  embraces
ifferent  clinical  entities  such  as  eosinophilic  pneumonia,
hronic  organizing  pneumonia  (COP),  acute  fibrinous  orga-
izing  pneumonia  (AFOP),  nonspecific  interstitial  pneumonia
NSIP)-like  and  idiopathic  pulmonary  fibrosis  (IPF)-like  inter-ced  amiodarone-induced  pneumopathy.  Pulmonol.  2019.
titial  pneumonia,  desquamative  interstitial  pneumonia
DIP),  acute  respiratory  distress  syndrome  (ARDS),  diffuse
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nodular  or  mass-like  lesions.2,4,5 Amiodarone-related  pul-
monary  nodules  usually  generate  high  attenuation  areas  on
CT  scans  due  to  the  incorporation  of  iodine-rich  amiodarone
into  type  II  pneumocytes.6 In  this  form,  the  radiological
presentation  of  drug-induced  toxicity  might  mimic  malig-
nant  neoplasms.7 In  most  cases,  patients  respond  well
to  the  withdrawal  of  amiodarone  with  the  addition  of
corticosteroid  treatment,  with  symptoms  and  radiological
abnormalities  resolving  within  several  months  due  to  the
long  half-life  of  the  amiodarone  metabolites.8
The  peculiarity  of  our  case  was  the  sequential  occur-
rence  of  reversible  interstitial  NSIP-like  lung  abnormalities
followed  by  nodular  high-density  opacities.  Moreover,  the
onset  of  lung  nodules  occurred  after  the  withdrawal  of
amiodarone  and  once  corticosteroid  treatment  had  been
started.  Several  hypotheses  on  the  late-onset  of  lung  nod-
ules  could  be  made.  A  late-onset  direct  toxic  injury  to  lung
parenchyma  and/or  a  slow  immunologic  reaction  should  not
be  excluded.2 However  given  that  the  nodules  were  located
in  the  same  lobe  where  the  first  biopsy  had  been  performed,
a  possible  increase  in  lung  susceptibility  to  amiodarone  toxic
effect  after  physical  insult  might  be  suspected.1
To  the  best  of  our  knowledge,  this  is  the  first  case  of  a
biphasic  manifestation  of  amiodarone-related  lung  toxicity
with  large  reversible  nodules  following  interstitial  abnor-
malities.  The  broad  imaging  manifestations  of  APT  may
account  for  some  temporal  heterogeneity.
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